IASO206 in Patients With Relapsed/Refractory Multiple Myeloma
Status:
NOT_YET_RECRUITING
Trial end date:
2028-10-15
Target enrollment:
Participant gender:
Summary
This study is an open-label, single-arm early exploratory clinical study, aiming to evaluate the safety, tolerability and preliminary efficacy of IASO206 Injection(In Vivo CAR-T) in Patients with Relapsed/Refractory Multiple Myeloma
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China